[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Advanced Medical Solutions Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,71,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100615651","liquiband-fix8-for-ventral-incisional-hernia-100615651",false,"NCT07295379","LIQUIBAND FIX8® for Ventral Incisional Hernia","A Retrospective, Single Centre, Observational Study to Evaluate the Safety and Effectiveness of LIQUIBAND FIX8® When Used for Mesh Fixation During Ventral Incisional Hernia Repair.","LBF8-03","Inclusion Criteria:\n\n* Patient is ≥ 18 years of age and ≤ 80 years of age.\n* Patient had a ventral incisional hernia (this may include both primary and recurrent).\n* Patient underwent a ventral incisional repair and LIQUIBAND FIX8® adhesive was used for mesh fixation (including those patients where supplemental fixation was used)\n* Has a minimum of 12 months follow-up.\n\nExclusion Criteria:\n\n* Every patient who required a ventral incisional hernia repair without concomitant parastomal hernia repair that meets the eligibility criteria will be included in this study. There will be no exclusions specific to the device. Any exclusions relating to device labelling, will have been established as part of the patient's standard of care, prior to the surgical procedure.","ALL","18 Years","80 Years",{"count":21,"type":22},148,"ESTIMATED","OBSERVATIONAL","This study is designed to evaluate the safety and performance of device LiquiBand FIX8 Open hernia mesh fixation device. The use of this device is not experimental, as it is already approved for use in the EU (CE-marked). This is a retrospective post market clinical follow-up study to collect information about the use of the device in a real-world setting for ventral incisional hernia repair. Ventral incisional hernias occur following surgery and the most common method of treatment includes implanting a mesh, which in the case of ventral incisional hernia, the standard of care is intra-peritoneal onlay mesh. This is fixed in place using sutures, tacks or adhesive.\n\nThe LiquiBand FIX8 Open device is an atraumatic device specifically engineered for strong mesh fixation of hernia repair meshes. Hernia repair meshes are woven sheets of flexible synthetic plastic which are placed tension-free over the weakness in the peritoneum abdominal wall, essentially 'plugging' it up. Tension is created in the abdominal wall during repair, but the mesh allows this tension to be spread out. The mesh must be secured to the underlying tissue and this is often done with the use of tacks or sutures, however, the study device instead uses a glue (N-Butyl 2 cyanoacrylate adhesive) to secure the mesh. The FIX8 Open device is designed for the application of this glue to the implanted hernia repair mesh in order to fix the mesh to the underlying tissue. When the glue is applied to the mesh and tissue, it polymerises (forms a chemical bond) due to the moisture on the tissue surface within approximately 10 seconds and allows the mesh to remain in the correct position. The study device can also be used to close topical wounds (the opening that the surgeon makes on the surface to access the hernia).",[26],"Hernia Incisional Ventral","NOT_YET_RECRUITING","2025-12-08",{"date":30,"type":31},"2025-12-19","ACTUAL",{"date":33,"type":22},"2025-12-20",{"date":35,"type":22},"2026-04-30",{"name":37,"class":38},"Advanced Medical Solutions Ltd.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100612619","pmcf-study-of-debridement-pad-100612619","NCT07255937","PMCF Study of Debridement Pad","Post Market Clinical Follow up Study to Confirm the Ongoing Safety and Performance of a Debridement Pad in Superficial, Chronic and Acute Wounds","Inclusion Criteria:\n\n* Males or females aged 18 years or above.\n* Patients who can understand and give informed consent to take part in the study.\n* Have one or more of the following wounds: Diabetic ulcers, Arterial and Venous Leg ulcers, Pressure ulcers, Postoperative wounds healing by secondary intention, traumatic and surgical wounds, and burns and scalds\n* Wounds that require debridement due to the presence of slough debris\u002Ffibrous tissue ,hyperkeratotic debris and dried exudate on the peri wound skin.\n* Wounds with both serous crusts and healthy tissue.\n* Minimum of 30% of the wound covered by debris, necrosis or slough.\n* Wound Size \\> 4cm2\n\nExclusion Criteria:\n\n* Patients who are known to be non-compliant with medical treatment\n* Patients who are known to be sensitive to any of the device components such as polyester.\n* Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with their ability to participate in the study.\n* Subject is currently enrolled in another clinical study, or has completed a clinical study less than 30 days prior to enrolment.\n* Symptoms \\& signs of systemic and \u002F or spreading wound infection (including erythema and fever).\n* Severe pain (level 7 or higher on a 0-10 VAS or hyperaesthesia in the wound area).\n* Subjects who in the view of the investigator might not be suitable for inclusion in the study",{"count":48,"type":22},184,"INTERVENTIONAL",[51],"NA","The design of the study is a clinical trial of Debridement Pad in subjects with superficial, chronic and acute wounds consisting of Diabetic ulcers, Arterial and Venous Leg ulcers, Pressure ulcers, Postoperative wounds healing by secondary intention, traumatic or surgical wounds and burns and scalds. The performance data from this study will support clinically meaningful rates of successful improvement in wound bed condition immediately after treatment.",[54,55,56,57,58,59,60,61],"Diabetic Ulcers","Venous Leg Ulcer","Arterial Leg Ulcer","Pressure Ulcer","Postoperative Wound Healing","Traumatic Wounds","Surgical Wounds","Burns and Scalds","RECRUITING","2025-11-27",{"date":65,"type":31},"2025-12-01",{"date":67,"type":31},"2025-11-20",{"date":69,"type":22},"2026-07-10",{"name":37,"class":38},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100600699","seal-g-seal-g-mist-long-term-follow-up-pmcf-continue-study-100600699","NCT07100886","Seal-G\u002F Seal-G MIST Long-Term Follow-up PMCF (Continue) Study","Long-Term Safety and Efficacy Evaluation of Seal-G and Seal-G MIST Surgical Sealants for Anastomosis Protection in Colon Surgery [PMCF Study Continuation]","Inclusion Criteria:\n\n* Treatment Group: Patients participated and completed all visits in the previous PMCF study (treatment group; #DLG-072-06)\n* Control Group: comparable retrospective subjects that meet the same inclusion criteria specified in #DLG-072-06.\n* Both Treatment \\& Control group:\n\nWilling to comply with long-term follow-up assessment (including oral consent).\n\nExclusion Criteria:\n\n* Both Treatment \\& Control group:\n\nPatients who are unable or unwilling to complete the phone questionnaire.\n\n\\- Control group: Subjects that would have been excluded according to the previous PMCF study #DLG-072-06 exclusion criteria.\n\n* Patients with missing or incomplete medical records that prevent retrospective comparison.\n* Patients that during the original surgery received any treatment on the anastomosis (sealant\u002Fglue) except for the anastomosis closure technique (sutures\u002Fstaple).\n* Original surgery included stoma creation.","85 Years",{"count":80,"type":22},208,"Postoperative complications following colon anastomosis surgery, such as adhesions, stenosis, stricture and obstruction, can significantly impact patient outcomes. The use of surgical sealants has been proposed as a means to mitigate anastomotic complications by providing a protective barrier over the anastomosis site, reducing the risk or the severity of anastomotic leak. The previous post-market clinical follow-up (PMCF) study assessed the short-term safety and performance of SEAL-G surgical sealants in preventing anastomotic leaks and early post-operative complications. However, long-term data are needed to establish its sustained safety and effectiveness.\n\nThis continuation study aims to evaluate the long-term impact of the SEAL-G\u002FMIST surgical sealant on post-operative complications over 12+ months after surgery. The study will compare complication rates in patients treated with the surgical sealant to a retrospective comparable control group who underwent similar procedures without the sealant.",[83],"Colon Anastomosis","2025-07-28",{"date":86,"type":31},"2025-08-03",{"date":88,"type":22},"2025-08-04",{"date":90,"type":22},"2026-01-30",{"name":37,"class":38},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":101,"conditions":102,"keywords":106,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100541205","inoss-mbcp-putty-ortho-100541205","NCT06326827","In'Oss™ (MBCP® Putty) Ortho","Study of the Osteoconductive Potential of the Injectable Bone Substitute In'Oss™ (MBCP® Putty) in the Filling of Orthopaedic Bone Defects","Inclusion Criteria:\n\n1. Patient is male or female, 18 - 85 years old;\n2. Patient is willing and able to give written informed consent;\n3. Patient is able to comply with a prior medical examination;\n4. Patient is or has been scheduled for a surgical procedure to correct epiphyso-metaphyseal and\u002For metaphyso-diaphyseal bone defect in one of the following anatomical locations:\n\n   * Proximal humerus ▪ Distal radius\n   * Distal femur ▪ Proximal tibia ▪ Distal tibia\n5. Patient is willing and able to comply with the study procedures during surgery and the post-surgical follow up period, up to 12 months.\n\nExclusion Criteria:\n\n1. Patient has had an infection in the same extremity within last 24 months;\n2. Patient has signs of necrosis at the surgical site;\n3. Patient has cellulitis;\n4. Patient has granuloma or non-curetted cyst;\n5. Patient has an history of uncontrolled diabetes;\n6. Patient is alcoholic and\u002For heavy smoker (\\> 20 cigarettes per day);\n7. Patient has a congenital or acquired immunodeficiency;\n8. Patient has severe bone loss (≥ 40cm3);\n9. Patient is on long-term steroidal therapy or treatment acting on the calcium or phosphorus metabolism;\n10. Patient is or has been scheduled for surgery that would involve intra-articular implantation of the study device;\n11. Patient who has or had an uncontained bone defect created as a result of trauma injury or surgically created;\n12. Patient was exposed to any radiation (e.g. X-Rays, handling of radiolabelled materials) other than the normal background radiation within the 12 months before the screening visit;\n13. Patient is pregnant;\n14. Patient who is an employee at the study site;\n15. Patient is known to be non-compliant with medical treatment or follow-up\n16. Patient has any significant or unstable medical\u002Fpsychiatric condition that, in the opinion of the Investigator, would interfere with their ability to participate in the study;\n17. Patient is currently enrolled or planning to enrol in another clinical study or treatment with another investigational drug\u002Fdevice that may interfere with the assessments, visits or outcomes of this study.",{"count":100,"type":22},100,"Study of the osteoconductive potential of the injectable bone substitute In'Oss™ (MBCP® Putty) in the filling of orthopaedic bone defects to collect Post-Market Clinical Follow-up (PMCF) data for the CE-marked In'Oss™ (MBCP® Putty) device in the orthopaedic trauma surgery",[103,104,105],"Orthopedic Disorder","Trauma Injury","Extremity Injury",[107,108,109,110,111,112,113,114],"Proximal humerus","Distal radius","Distal femur","Proximal tibia","Distal tibia","Fracture","MBCP Putty","Bone defect reconstruction","2025-02-03",{"date":117,"type":31},"2025-02-05",{"date":119,"type":22},"2025-03",{"date":121,"type":22},"2027-03",{"name":37,"class":38},""]